From Financialpost · · 1m 10s
Hologic Acquires Reveal Genomics for Breast Cancer Diagnostics
Hologic to buy Reveal Genomics, expanding breast cancer testing for women.
In brief
Hologic to buy Reveal Genomics, expanding breast cancer testing for women. Hologic acquires Reveal Genomics to expand precision oncology diagnostics for breast cancer treatment decisions. Originally reported by Financialpost.
Hologic Announces Acquisition
Hologic, a global leader in women’s health, signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain.
Reveal Genomics’ Role in Breast Cancer
Reveal Genomics develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test for HER2-positive breast cancer.
Hologic’s Existing Diagnostics
Hologic’s Breast Cancer Index ® (BCI) test helps inform decisions regarding extended endocrine therapy for HR+ early-stage breast cancer.
Strategic Expansion
The combination of Hologic’s testing with Reveal Genomics’ portfolio expands diagnostic oncology solutions to help more women with breast cancer.
CEO Statements
Vitor Rocha, CEO of Hologic’s Diagnostic Solutions, said Reveal Genomics’ portfolio complements Hologic’s oncology offering and expands treatment decision capabilities.
Reveal Genomics’ Vision
Patricia Villagrasa-Gonzalez, CEO and co-founder of Reveal Genomics, stated joining Hologic accelerates their mission to improve breast cancer treatment decisions globally.
Regulatory Conditions
Completion of the acquisition requires Spanish regulatory approval and other customary closing conditions.
In short
Hologic acquires Reveal Genomics to expand precision oncology diagnostics for breast cancer treatment decisions.
